CoChat
Sign Up
Cited by 195Parkinson's Disease Mechanisms and TreatmentsNeurotransmitter Receptor Influence on BehaviorDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 962 of the 962 references it cites were found in a registry or an index.

The serotonergic system in Parkinson's disease

Huot, Philippe, Fox, Susan H., Brotchie, Jonathan M.·2011·Progress in Neurobiology
DOI 10.1016/j.pneurobio.2011.08.004
Open this paper in CoChat — free account

Abstract

Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline in dopamine levels in the striatum, a breadth of non-motor features and treatment-related complications in which the serotonergic system plays a pivotal role are increasingly recognised. Serotonin (5-HT)-mediated neurotransmission is altered in PD and the roles of the different 5-HT receptor subtypes in disease manifestations have been investigated. The aims of this article are to summarise and discuss all published preclinical and clinical studies that have investigated the serotonergic system in PD and related animal models, in order to recapitulate the state of the current knowledge and to identify areas that need further research and understanding.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pneurobio.2011.08.004

Cites

962 of 962 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 401–600 of 962

Research works printed but not linked: 119

  1. Agarwal, 2008, Aripiprazole induced tardive dyskinesia in a patient with Parkinson's disease, Mov. Disord., 23, S236
  2. Alter, 2010, Serotonergic dysfunction in the VMAT2-deficient Parkinson's disease mouse model, Soc. Neurosci.
  3. Ansah, 2007, Acute but not subchronic MPTP administration decreases serotonin in the prefrontal cortex, Soc. Neurosci.
  4. Auff, 1987, Ritanserin in the treatment of tremor-dominant Parkinson's disease: a preliminary study, New Trends Clin. Neuropharmacol., 1, 149
  5. Ballanger, 2011, Role of serotoninergic dysfunction in the pathophysiology of depression in Parkinson's disease: a PET 18F-MPPF study, Mov. Disord., 26, S252
  6. Ballanger, 2008, Investigating 5HT2A receptor binding in PD patients with visual hallucinations: a [18F]setoperone PET study, Mov. Disord., 23, S75
  7. Bartoszyk, 2006, Sarizotan reduces dyskinesia and maintains antiparkinsonian efficacy of levodopa in MPTP monkeys, Mov. Disord., 21, S595
  8. Bartoszyk, 2006, Sarizotan exhibits functional selectivity at D2, D3 and D4 dopamine receptors: relevance for its antidyskinetic mechanism of action, Mov. Disord., 21, S570
  9. Bartoszyk, 2006, Mechanism of the antidyskinetic efficacy of sarizotan in hemiparkinsonian rats, Mov. Disord., 21, S495
  10. Bishop, 2009, Chronic l-dopa treatment modifies serotonin function in depression-related structures of the hemiparkinsonian rat brain, Mov. Disord., 24, S27
  11. Bishop, 2008, l-DOPA treatment reduces serotonin function in depression-related structures of the hemiparkinsonian rat, Soc. Neurosci.
  12. Bishop, 2007, Direct striatal 5-HT1A receptor stimulation reduces l-DOPA-induced dyskinesia in the hemiparkinsonian rat, Soc. Neurosci.
  13. Bocquillon, 2009, A 5HT2A polymorphism is associated with pathological gambling in Parkinson's disease, Mov. Disord., 24, S241
  14. Bonhaus, 2009, Pimavanserin: a selective 5-HT2A inverse agonist has antipsychotic like activity in animal models of Parkinson's disease (PD) and reduces psychotic symptoms in PD patients, Soc. Neurosci.
  15. Bonuccelli, 1994, Clozapine use in extrapyramidal disorders, Mov. Disord., 9, S60
  16. Brewer, 1995, Safety and effectiveness of clozapine for parkinsonian patients with psychosis, Neurology, 45, A252
  17. Bronzova, 2008, Pardoprunox (SLV308) improves motor symptoms in patients with early stage Parkinson's disease—a double-blind, placebo-controlled multi-center study, AAN Annual Meeting [P02.028]
  18. Bronzova, 2008, Pardoprunox (SLV308) in patients with early stage Parkinson's disease—a double-blind, placebo-controlled, multicenter study by the Bruegel study group, Mov. Disord., 23, S194
  19. Bronzova, 2010, Pardoprunox adjunctive to l-dopa for treating motor symptoms in advanced PD: results from a randomized, double-blind, placebo-controlled study, Mov. Disord., 25, S291
  20. Button, 2009, Effect of serotonin 1A receptor stimulation on pERK1/2 in the DA-depleted striatum, Soc. Neurosci.
  21. Carta, 2009, Serotonin neuron-dependent and -independent reduction in dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model, Soc. Neurosci.
  22. Chacon, 2004, Clozapine and olanzapine in the treatment of the psychotic disorders in Parkinson's disease, Rev. Neurol., 39, 655
  23. Chase, 1970, Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism, Neurology, 20, 36, 10.1212/WNL.20.12_Part_2.36 · DOI
  24. Cudkowicz, 1996, Clozapine versus risperidone in the treatment of psychosis in Parkinson's disease, Neurology, 46, A376
  25. Dupre, 2009, 5-HT1A receptor stimulation reduces l-DOPA-induced striatal glutamate efflux in the hemiparkinsonian rat, Soc. Neurosci.
  26. Dupre, 2010, Effects of 5-HT1A receptor stimulation on striatal NMDA receptor subunit expression and markers of D1 receptor-mediated dyskinesia, Soc. Neurosci.
  27. Dupre, 2008, Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat, Soc. Neurosci.
  28. Dupre, 2007, The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the hemiparkinsonian rat, Soc. Neurosci.
  29. Durif, 1996, Levodopa-induced dyskinesias are improved by low-dose clozapine, Neurology, 46, A476
  30. Eskow Jaunarajs, 2010, Chronic l-DOPA reduces tryptophan hydroxylase-2 expression in the dorsal raphe nucleus in a bilateral rat model of Parkinson's disease, Soc. Neurosci.
  31. Eskow, 2007, Serotonin 5-HT1A receptor stimulation of the dorsal raphe nucleus decreases l-DOPA-induced dyskinesia in the hemiparkinsonian rat, Soc. Neurosci.
  32. Eskow, 2008, Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat, Soc. Neurosci.
  33. Evatt, 1996, “Seroquel” (ICl 204,636) treatment of psychosis in parkinsonism, Mov. Disord., 11, 595
  34. Factor, 1992, Psychosis in Parkinson's disease: long term therapy with clozapine, Mov. Disord., 7, 100
  35. Ferguson, 2010, 5-HT2A receptor antagonist M100907 decreases striatal extracellular glutamate in MPTP mouse model of Parkinson's disease, Soc. Neurosci.
  36. Ferguson, 2008, Motor deficits in MPTP-treated mice: modulation by serotonergic agents, Soc. Neurosci.
  37. Ferguson, 2009, Selective 5-HT2A receptor antagonists decrease motor deficits in MPTP mouse model of Parkinson's disease, Soc. Neurosci.
  38. Fernandez, 2009, Quetiapine improves visual hallucinations in PD, but not through normalization of sleep architecture: results from a double-blind polysomnography study, Mov. Disord., 24, S238
  39. Friedman, 2011, Treating idiopathic Parkinson's disease (IPD) in patients with schizophrenia, Mov. Disord., 26, S257
  40. Friedman, 1996, BCLOZ: a double-blind, crossover trial comparing clozapine with benztropine for treatment in Parkinson's disease, Neurology, 46, A476
  41. Friedman, 1990, Clozapine treatment of tremor in Parkinson's disease, Mov. Disord., 5, S50
  42. Friedman, 1992, Clozapine for movement disorder patients: a retrospective analysis of 38 patients, Ann. Neurol., 32, 277
  43. Friedman, 2010, A multi-center, placebo-controlled, double-blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson's disease, Mov. Disord., 25, S292
  44. Fujimoto, 2008, Safety and efficacy of mianserine on psychosis in Parkinson's disease, Mov. Disord., 23, S214
  45. Fujimoto, 2000, Mianserin therapy for psychosis in parkinsonism, Neurol. Med., 53, 274
  46. Gershanik, 1992, Analysis of the mechanism of action of clozapine in Parkinson's disease, Mov. Disord., 7, 101
  47. Gershanik, 1978, The role of serotonin in the action of l-dopa in an animal model of parkinsonism, Neurology, 29, S553
  48. Gimenez-Roldan, 2003, Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease, Rev. Neurol., 36, 401
  49. Goetz, 2006, Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo controlled trial, Mov. Disord., 21, S606
  50. Gomide, 2007, Use of clozapine in Brazilian patients with Parkinson's disease, Mov. Disord., 22, S174
  51. Grandas, 2008, Dopaminergic dysregulation syndrome after deep brain stimulation for Parkinson's disease, Mov. Disord., 23, S120
  52. Gregoire, 2010, The role of 5-HT2A receptors in the MPTP monkey model of Parkinson's disease and l-Dopa induced dyskinesia, Soc. Neurosci.
  53. Haapaniemi, 2001, [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients, Mov. Disord., 16, 124, 10.1002/1531-8257(200101)16:1<124::AID-MDS1007>3.0.CO;2-R · DOI
  54. Hauser, 2008, Impact of titration regimen on the safety and tolerability of pardoprunox (SLV308) in patients with advanced Parkinson's disease (PD), Mov. Disord., 23, S207
  55. Hoshiyama, 2008, Refractory olfactory hallucination in a patient with Parkinson's disease: three years follow-up, Mov. Disord., 23, S105
  56. Huot, 2010, The selective D4 receptor antagonist L-745,870 alleviates the severity of l-DOPA-induced dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease, Soc. Neurosci.
  57. Huot, 2010, Speculations on the role of serotonergic 5-HT1A- and 5-HT2A-mediated neurotransmission in parkinsonism and dyskinesia, Soc. Neurosci.
  58. Huot, 2010, 5-HT1A receptor levels are altered in both the dopamine-depleted and dyskinetic states in the MPTP-lesioned macaque model of Parkinson's disease, Mov. Disord., 25, S414
  59. Huot, 2011, The 5-HT2A partial agonist R-MDMA reduces psychosis-like behaviour in the MPTP-lesioned non-human primate model of Parkinson's disease, Mov. Disord., 26, S281
  60. Huot, 2010, Effects of R- and S-MDMA on l-DOPA-induced dyskinesia and duration of on-time in the MPTP-lesioned common marmoset, Soc. Neurosci.
  61. Huot, 2010, 5-HT2A receptor levels are increased in dyskinetic, MPTP-lesioned macaques, Mov. Disord., 25, S414
  62. Jackson, 2008, The effect of pardoprunox (SLV308) treatment on l-dopa induced dyskinesia in MPTP-treated common marmosets, a chronic study, Mov. Disord., 23, S306
  63. Jha, 2008, A case of compulsion to self-harm related to dopaminergic therapy—a new dopaminergic impulse-control disorder, Mov. Disord., 23, S282
  64. Juncos, 1996, Clozapine treatment of parkinsonian pain syndromes, Mov. Disord., 11, 603
  65. Juncos, 1999, Quetiapine improves psychotic symptoms associated with Parkinson's disease, Neurology, 52, A262
  66. Juncos, 1998, Long term effect of quetiapine fumarate in parkinsonism complicated by psychosis, Neurology, 50, A70
  67. Klein, 2007, Naturalistic long term follow-up of psychotic Parkinson's disease patients treated with either clozapine or quetiapine, Mov. Disord., 22, S153
  68. Koller, 1994, Low dose clozapine in the treatment of levodopa-induced psychosis, Mov. Disord., 9, S64
  69. Lee, 2011, Role of serotonin receptor 2A gene variants in the impulsive compulsive behaviors (ICB) in Parkinson's disease (PD), Mov. Disord., 26, S311
  70. Lew, 1992, Treatment of parkinsonism with psychosis using clozapine, Mov. Disord., 7, 100
  71. Linazasoro, 1992, Clozapine in Parkinson's disease: three years experience, Mov. Disord., 7, 100
  72. Lindgren, 2008, Serotonergic modulation of striatal dopamine release and metabolism in a rat model of l-DOPA-induced dyskinesia, Soc. Neurosci.
  73. Lopez del Val, 2004, Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease, Rev. Neurol., 39, 661
  74. Maeda, 2009, Systemic l-dopa deplete the striatal serotonin release in rats with nigro-striatal dopaminergic denervation, Mov. Disord., 24, S355
  75. Maeda, 2010, Systemic L-DOPA deplete the striatal serotonin release in rats with nigro-striatal dopaminergic denervation, Mov. Disord., 25, S416
  76. Maloteaux, 1985, S2-serotonin receptors in frontal cortex of parkinsonian patients, J. Neurol., 32, 108
  77. Marek, 2009, Sparing of serotonin and norepinephrine transporter uptake compared to dopamine transporter uptake in early Parkinson's disease, Mov. Disord., 24, S199
  78. Marin, 2008, Subthalamic administration of sarizotan attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats, Mov. Disord., 23, S315
  79. Masilamoni, 2011, A nonhuman primate model of Parkinson's disease associated with cortical and subcortical dopaminergic, noradrenergic and serotonergic neuronal degeneration, Mov. Disord., 26, S23
  80. McCreary, 2010, Pardoprunox: effects on motor and non-motor symptoms of Parkinson's disease, Mov. Disord., 25, S403
  81. Meco, 1994, Risperidone for hallucinations in l-DOPA-treated Parkinson's disease patients, Mov. Disord., 9, S61
  82. Merims, 2005, Rater-blinded, prospective study comparing the therapeutic benefit of clozapine vs. quetiapine on psychosis in patients with Parkinson's disease, Mov. Disord., 20, S127
  83. Mills, 2010, An interim analysis of an open-label extension study to examine the the long-term safety and tolerability of pimavanserin in the treatment of Parkinson's disease psychosis, Mov. Disord., 25, S302
  84. Mills, 2008, An open-label extension study to determine the safety of pimavanserin in patients with Parkinson's disease and psychosis, Mov. Disord., 23, S221
  85. Mills, 2009, An open-label extension study to determine the safety of pimavanserin in patients with Parkinson's disease and psychosis, Mov. Disord., 24, S269
  86. Mills, 2008, A double-blind, placebo-controlled, dose-escalation trial of pimavanserin in Parkinson's disease and psychosis, Mov. Disord., 23, S221
  87. Morgante, 2007, Anti-psychotic treatment discontinuation and drug-induced psychosis in Parkinson's disease, Mov. Disord., 22, S232
  88. Muller, 2006, The PADDY-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in Parkinson's disease patients, Mov. Disord., 21, S591
  89. Nayyar, 2008, Modulation of serotonergic system in the MPTP mouse model of Parkinson's disease, Soc. Neurosci.
  90. Ostock, 2010, The effects of 5-HT1A receptor stimulation on l-DOPA-induced c-fos expression within the hemiparkinsonian rat brain, Soc. Neurosci.
  91. Ostock, 2009, 5-HT1A receptor stimulation within the primary motor cortex reduces l-DOPA-induced dyskinesias in the hemiparkinsonian rat, Soc. Neurosci.
  92. Paquette, 2007, Differential effects of NMDA antagonists and sigma ligands on l-DOPA-induced dyskinesias and functional improvement in the hemiparkinsonian rat, Soc. Neurosci.
  93. Paquette, 2009, Effects of 5-HT1A agonism and NDMA antagonism on l-DOPA-induced dyskinesia and sensorimotor behavior in the 6-OHDA rat, Soc. Neurosci.
  94. Paquette, 2010, NMDA antagonism versus 5-HT1A agonism: suppressing l-DOPA-induced dyskinesia without exacerbating parkinsonism in the 6-OHDA rat, Soc. Neurosci.
  95. Patel, 1994, Localization of 5-HT4 receptors in the striato-nigral pathway in rat brain, Br. J. Pharmacol., 113, 135
  96. Pavese, 2010, Serotonin and fatigue in Parkinson's disease. An exploratory study, Mov. Disord., 25, S389
  97. Rabey, 2009, The use of dopamine agonists (DAGs) in “de novo” Parkinson's disease patients (PDpts) first diagnosed after 70years old, Mov. Disord., 24, S226
  98. Rascol, 2006, A large phase III study to evaluate the safety and efficacy of sarizotan in the treatment of l-dopa-induced dyskinesia associated with Parkinson's disease: the Paddy-1 study, Mov. Disord., 21, S492
  99. Riahi, 2010, 5-HT1B receptors in a non-human primate model of l-Dopa induced dyskinesia, Soc. Neurosci.
  100. Rui Silva, 1995, Clozapine in the treatment of psychosis in parkinsonism, J. Neurol., 242, 138
  101. Rylander, 2008, l-DOPA-induced dyskinesia in a rat model of Parkinson's disease; correlation with indexes of dopaminergic and serotonergic transmission, Soc. Neurosci.
  102. Sage, 2009, Pilot study of the efficacy and safety of piclozotan in Parkinson's disease patients with l-dopa induced motor complications, Mov. Disord., 24, S277
  103. Sahin, 2010, Grafted serotonin neurons aggravate l-DOPA-induced dyskinesia: in vivo evidence by microdialysis and [18F]fallypride PET imaging, Mov. Disord., 25, S268
  104. Sampaio, 2010, Pardoprunox in early stage Parkinson's disease: results from two large studies, Mov. Disord., 25, S308
  105. Sano, 1972, l-5-Hydroxytryptophan (L-5-HTP)-therapie des morbus Parkinson, Zweite Mitteilung. Munch Med. Wschr., 114, 1717
  106. Simoes, 1992, Clozapine in the treatment of patients with tremor (parkinsonian, essential, and neuroleptical-induced), Mov. Disord., 7, S47
  107. Stockwell, 2008, Investigation of the chronic effect of pardoprunox (SLV308) treatment upon l-DOPA-induced dyskinesia in MPTP-treated common marmosets, Soc. Neurosci.
  108. Stromberg, 2007, l-DOPA conversion to dopamine in the dopamine- and 5-HT depleted rat striatum, Soc. Neurosci.
  109. Svenningsson, 2008, Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in parkinsonism, Soc. Neurosci.
  110. Tani, 2009, Piclozotan (SUN N4057), a 5-HT1A receptor agonist, improves motor complications induced by repeated administration of levodopa without reducing levodopa efficacy in parkinsonian rats, Mov. Disord., 24, S49
  111. Tolleson, 2011, Efficacy of atypical neuroleptics and acetylcholinesterase inhibitors in treating neuropsychiatric symptoms in Parkinson's disease, Mov. Disord., 26, S166
  112. Trosch, 1996, Clozapine use in Parkinson's disease, Neurology, 46, A375
  113. Valis, 2008, Comorbidity of Parkinson's disease and schizophrenia spectrum disorders, Mov. Disord., 23, S280
  114. von Ameln-Mayerhofer, 2009, The antiparkinsonian effects of 3,4-methylenedioxymethamphetamine in rats: role of 5-HT1A-receptors, serotonin transporter and neurochemical effects, Behav. Pharmacol., 20, S107
  115. Wang, 2008, A study on cerebral neurotransmitters in patients with Parkinson's disease, Mov. Disord., 23, S306
  116. Weiner, 1998, Olanzepine for the treatment of hallucinations/delusions in Parkinson's disease, Mov. Disord., 13, 862
  117. Yamamoto, 2010, Dramatically efficacy of deep brain stimulation for a patient with Parkinson's disease with olfactory hallucination, Mov. Disord., 24, S477
  118. Zangaglia, 2006, REM “sleep behaviour disorder” (RBD) and somniloquy in Parkinson's disease: efficacy of quetiapine, Mov. Disord., 21, S652
  119. Zeng, 2008, Morphological changes in serotonergic neurites in the striatum of levodopa primed MPTP-treated common marmosets, Soc. Neurosci.

Cited by

Sorted by citations

See all 195

Related

See all

Metadata

Authors
Huot, P., Fox, S. H., & Brotchie, J. M.
Affiliations
University Health Network (CA)
Corresponding author
Brotchie, Jonathan M.
ORCID
Venue
Progress in Neurobiology
Publisher
Elsevier BV
Published
2011-10
Volume
95
Issue
2
Pages
163-212
ISSN
0301-0082 (ISSN-L)
DOI
10.1016/j.pneurobio.2011.08.004
OpenAlex
W1970083936
Cited by
195
References
962
Citations by year
2026: 6 · 2025: 11 · 2024: 10 · 2023: 9 · 2022: 14 · 2021: 8 · 2020: 10 · 2019: 13 · 2018: 8 · 2017: 14 · 2016: 16 · 2015: 19 · 2014: 19 · 2013: 20 · 2012: 14
FWCI
2.22
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Progress in Neurobiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
Parkinson's disease, serotonergic system, serotonin, 5-HT receptor subtypes, non-motor symptoms, treatment complications, dopamine depletion, striatum, animal models
MeSH terms
Animals, Disease Models, Animal, Humans, Synaptic Transmission, Parkinson Disease, Receptors, Serotonin, Serotonin, Protein Isoforms, Molecular Targeted Therapy, Serotonergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review